* Treace Medical Concepts Inc TMCI.OQ TMCI.O is expected
to show a rise in quarterly revenue when it reports results on
August 8.
* The Ponte Vedra Florida-based company is expected to
report a
36.3% increase in revenue to $40.848 million from $29.97 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Treace Medical
Concepts
Inc is for a loss of 24 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Treace
Medical
Concepts Inc is $30, above its last closing price of $20.75.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.23 -0.23 -0.23 Met -0.7
Dec. 31 2023 -0.15 -0.14 -0.08 Beat 42.9
Sep. 30 2022 -0.29 -0.29 -0.22 Beat 23.5
Jun. 30 2022 -0.19 -0.20 -0.31 Missed -51.2
Mar. -0.21 -0.20 -0.16 Beat 21
31 2022
Dec. 31 2021 -0.01 0.00 -0.12 Missed -2,300
Sep. 30 2021 -0.12 -0.12 -0.12 Met 0
Jun. 30 2021 -0.12 -0.12 -0.10 Beat 16.7
This summary was machine generated August 5 at 02:09 GMT. All
figures in US dollars unless otherwise stated